PF-562271

• Description :

  PF-562271 (VS-6062) is a potent, ATP-competitive and reversible FAK and Pyk2 kinase inhibitor with IC50s of 1.5 nM and 13 nM, respectively[1].

• Product Name Alternative :

  VS-6062

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  FAK; Pyk2

• Type :

  Reference compound

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/PF-562271.html

• Purity :

  99.36

• Solubility :

  DMSO : 66.67 mg/mL (ultrasonic)

• Smiles :

  CS(=O)(N(C)C1=NC=CC=C1CNC2=NC(NC3=CC4=C(C=C3)NC(C4)=O)=NC=C2C(F)(F)F)=O

• Molecular Formula :

  C21H20F3N7O3S

• Molecular Weight :

  507.49

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Roberts WG, et al. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Cancer Res, 2008, 68 (6), 1935-1944.|[2]Crompton BD, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013 May 1;73 (9) :2873-83.|[3]Bagi CM, et al. Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases. Cancer. 2008 May 15;112 (10) :2313-21.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Citation 01 :

  Am J Chin Med. 2025;53 (4) :1225-1240.|Anticancer Drugs. 2024 Jan 1;35 (1) :46-54.|bioRxiv. 2025 Apr 7:2025.04.01.646098.|bioRxiv. 2025 May 28.|Breast Cancer Res. 2024 Mar 19;26 (1) :48.|Cancer Med. 2025 Sep;14 (18) :e71227.|Cancer Res. 2013 May 1;73 (9) :2873-83.|Carbohydr Polym. 2024 Feb 15:326:121637.|Cell Death Dis. 2022 Sep 10;13 (9) :783.|Cell Death Dis. 2023 Feb 24;14 (2) :157.|Cell Discov. 2022 Sep 6;8 (1) :84.|Cell Rep. 2023 Oct 5;42 (10) :113213.|Cell Signal. 2025 Sep 10:136:112117.|Clin Cancer Res. 2019 Jul 15;25 (14) :4552-4566.|Environ Toxicol Pharmacol. 2023 Nov:104:104301.|Eur J Cell Biol. 2024 May 28;103 (2) :151427.|Harvard Medical School LINCS LIBRARY|Int J Cancer. 2015 Oct 1;137 (7) :1549-59.|Int J Surg. 2025 Sep 17.|J Nat Med. 2020 Sep;74 (4) :732-740.|Life Sci. 2021 Apr 1:270:119112.|Mol Biol Rep. 2025 May 14;52 (1) :458.|Nat Biomed Eng. 2025 Nov 3.|Practical Oncology Journal. 2015, 29 (5) : 444-449.|Res Sq. 2025 Jul 11.|Research Square Preprint. 2021 Dec.|Research Square Preprint. 2023 May 23.|Sci Rep. 2018 May 8;8 (1) :7228. |World J Gastroenterol. 2025 Jul 28;31 (28) :107361.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|University of Washington. 2025.

• CAS Number :

  [717907-75-0]